ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Add...
ACELYRIN, INC., a late- stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering
Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment